文献速递免疫规划

青少年和年轻成人中四价脑膜炎球菌疫苗MenACWY-TT与百白破联合疫苗同时接种与分开接种的免疫原性和安全性:一项III期随机研究

Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
PubMed 文献 · Vaccine · 2018-06-28

这项III期随机部分盲研究在660名11-25岁健康人中比较MenACWY-TT与Tdap同时接种或分开接种的免疫原性和安全性。同时接种对4个脑膜炎球菌血清群的rSBA GMTs及白喉、破伤风抗体浓度>1 IU/ml的受试者百分比达到非劣效;百日咳抗原中PT的GMCs达到非劣效,但FHA和PRN未达到。两种疫苗安全性可接受,研究支持在青少年中同时接种。

要点

  • 同时接种MenACWY-TT与Tdap对脑膜炎球菌4个血清群rSBA GMTs及白喉、破伤风抗体应答达到非劣效。
  • 百日咳PT的GMCs达到非劣效,但FHA和PRN未达到非劣效标准。
  • 所有组中≥93.2%对每个脑膜炎球菌血清群有疫苗应答,≥99.1%对破伤风和白喉血清保护,≥85.5%对每个百日咳抗原有加强应答。

核心结论

  • MenACWY-TT与Tdap同时接种不影响对MenACWY-TT及Tdap中破伤风和白喉抗原的免疫应答。
  • 观察到的百日咳组分抗体浓度较低可能临床相关性有限,因为观察到稳健的抗百日咳加强应答。
  • 本研究支持在青少年中同时接种这两种疫苗。

研究设计与样本

  • III期、随机、部分盲研究(NCT01767376),纳入660名11-25岁健康受试者,按1:1:1随机分为三组。
  • Co-ad组:第0月接种MenACWY-TT和Tdap;ACWY_Tdap组:第0月接种MenACWY-TT、第1月接种Tdap;Tdap_ACWY组:第0月接种Tdap、第1月接种MenACWY-TT。
  • 采用兔补体血清杀菌试验(rSBA)检测对MenACWY-TT的免疫应答,采用酶联免疫吸附试验检测抗白喉、抗破伤风、抗百日咳毒素(PT)、抗丝状血凝素(FHA)和抗pertactin(PRN)抗体浓度。
  • 采用预先定义的临床标准评估免疫原性的非劣效性,并评估安全性。

主要发现

  • 同时接种与分开接种相比,4个脑膜炎球菌血清群的rSBA几何平均滴度(GMTs)以及白喉和破伤风抗体浓度>1 IU/ml的受试者百分比达到非劣效。
  • 百日咳抗原中,PT的几何平均浓度(GMCs)达到非劣效标准,但FHA和PRN未达到。
  • 所有组中,≥93.2%的受试者对每个脑膜炎球菌血清群产生疫苗应答,≥99.1%对破伤风和白喉达到血清保护,≥85.5%对每个百日咳抗原产生加强应答。
  • 所有抗原在接种前后均观察到抗体GMTs/GMCs的稳健升高。
  • 两种疫苗均具有临床可接受的安全性特征。

关键数值与推荐

  • 免疫原性非劣效性依据预先定义的临床标准评估。
  • 脑膜炎球菌免疫应答采用rSBA检测,白喉、破伤风、百日咳抗体采用酶联免疫吸附试验检测。
  • 非劣效性在4个脑膜炎球菌血清群的rSBA GMTs及白喉和破伤风抗体浓度>1 IU/ml的受试者百分比上达到。
  • 百日咳PT的GMCs达到非劣效,FHA和PRN未达到非劣效。

临床怎么用

  • 本研究支持在青少年中同时接种MenACWY-TT和Tdap。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study evaluated the immunogenicity and safety of quadrivalent meningococcal conjugate vaccine using tetanus (T) toxoid as carrier protein (MenACWY-TT) co-administered with combined diphtheria-tetanus-acellular pertussis vaccine (Tdap) versus their separate administration in adolescents and young adults. METHODS: In this phase III, randomized, partially-blind study (NCT01767376), healthy 11-25-year-olds (N = 660) were randomized (1:1:1) to receive MenACWY-TT and Tdap at Month 0 (Co-ad group), MenACWY-TT at Month 0 and Tdap at Month 1 (ACWY_Tdap group) or Tdap at Month 0 and MenACWY-TT at Month 1 (Tdap_ACWY group). Immune responses to MenACWY-TT were measured by serum bactericidal assay using rabbit complement (rSBA). Anti-diphtheria (D), anti-tetanus (T), anti-pertussis toxin (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibody concentrations were assessed using enzyme-linked immunosorbent assays. Non-inferiority of immunogenicity was assessed using pre-defined clinical criteria. Safety was also evaluated. RESULTS: Non-inferiority of immunogenicity of MenACWY-TT and Tdap when co-administered versus their separate administration was demonstrated in terms of rSBA geometric mean titers (GMTs) for 4 meningococcal serogroups and of the percentage of participants with antibody concentrations >1 IU/ml for D and T. Among the pertussis antigens, non-inferiority criteria for geometric mean concentrations (GMCs) were reached for PT, but not met for FHA and PRN. Across all groups, ≥93.2% of participants had vaccine responses to each meningococcal serogroup, ≥99.1% were seroprotected against T and D, and ≥85.5% had booster responses to each pertussis antigen. Robust increases in antibody GMTs/GMCs were observed for all antigens between pre-and post-vaccination. Both vaccines had clinically acceptable safety profiles. CONCLUSION: Immune responses to MenACWY-TT and to the T and D antigens from Tdap were not impacted by their co-administration. The lower antibody concentrations observed against the pertussis components may be of limited clinical relevance since robust anti-pertussis booster responses were observed. This study supports concurrent administration of the 2 vaccines in adolescents.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rivera L, Schwarz TF, Kim KH, et al. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study. Vaccine. 2018. PMID: 29960800. doi:10.1016/j.vaccine.2018.04.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。